LDN and Cancer Documentary with Italian subtitles (Low dose naltrexone) from LDN Research Trust on Vimeo.

Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures

Adv Ther
18 December 2020
https://pubmed.ncbi.nlm.nih.gov/33337537/

Duration of opioid receptor blockade determines biotherapeutic response

J Clin Gastroenterol
October 2015
https://pubmed.ncbi.nlm.nih.gov/26119823/

Low-Dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study

Neuro Oncol
November 2015
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639177/

Naltrexone at low doses upregulates a unique gene expression not seen with normal doses: Implications for its use in cancer therapy

Int J Oncol
August 2016
https://www.ncbi.nlm.nih.gov/pubmed/27279602

Could Low-Dose Naltrexone be an Effective Treatment for Hailey-Hailey Disease?

Integ Biomed Sci
19 July 2016
https://www.gratisoa.org/journals/index.php/MML/article/view/1293/957

The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response

Int Immunopharmacol
January 2020
https://www.ncbi.nlm.nih.gov/pubmed/31835085

Low dose naltrexone (LDN) enhances maturation of bone marrow dendritic cells (BMDCs)

Int Immunopharmacol
December 2013
https://www.ncbi.nlm.nih.gov/pubmed/24455776

The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol

Integr Cancer Ther
March 2006
https://www.ncbi.nlm.nih.gov/pubmed/16484716

Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck

Head Neck
April 2012
https://pubmed.ncbi.nlm.nih.gov/21584896/